Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Anavex Life Sciences and Partex Group Announce Strategic Partnership

Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ

Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023

Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)

Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on February 7, 2023

Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial

Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS,

Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders

Anavex Life Sciences Provides Business Update & Reports Fiscal 2022 Third Quarter Financial Results